BR0014183A - Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada - Google Patents

Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada

Info

Publication number
BR0014183A
BR0014183A BR0014183-6A BR0014183A BR0014183A BR 0014183 A BR0014183 A BR 0014183A BR 0014183 A BR0014183 A BR 0014183A BR 0014183 A BR0014183 A BR 0014183A
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
secreted
related protein
sfrps
Prior art date
Application number
BR0014183-6A
Other languages
English (en)
Inventor
Peter V N Bodine
Original Assignee
American Home Pruducts Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Pruducts Corp filed Critical American Home Pruducts Corp
Publication of BR0014183A publication Critical patent/BR0014183A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: "COMPOSIçõES FARMACEUTICAS E MéTODOS DE USO DE PROTEìNA RELACIONADA FRIZZLED SECRETADA". São apresentadas composições farmacêuticas e métodos de uso na regulação de atividades de formação óssea em mamíferos, da SFRPs (proteínas relacionadas frizzied secretadas). As SFRPs são receptores secretados para Wnts, que são fatores de crescimento polipeptídicos importantes, que, como se conhece, regulam os processos biológicos fundamentais como polaridade tecidual, desenvolvimento embriónico e tumorigênese. Uma SFRP foi isolada em células de osteoblastos humanos e identificadas como SFRP-1 (também conhecida como SARP-2) e apresentada como sendo regulada por agentes osteogênicos nas células hOB de uma maneira seletiva de diferenciação modulando a vida de osteoblastos/pré-osteócitos.
BR0014183-6A 1999-09-13 2000-09-13 Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada BR0014183A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39483299A 1999-09-13 1999-09-13
PCT/US2000/025035 WO2001019855A2 (en) 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein

Publications (1)

Publication Number Publication Date
BR0014183A true BR0014183A (pt) 2002-05-14

Family

ID=23560597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014183-6A BR0014183A (pt) 1999-09-13 2000-09-13 Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada

Country Status (11)

Country Link
EP (1) EP1212355A2 (pt)
JP (1) JP2003512304A (pt)
CN (2) CN1387537A (pt)
AU (1) AU7131200A (pt)
BR (1) BR0014183A (pt)
CA (1) CA2383360A1 (pt)
CZ (1) CZ2002903A3 (pt)
IL (1) IL148421A0 (pt)
MX (1) MXPA02002624A (pt)
NZ (1) NZ529560A (pt)
WO (1) WO2001019855A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401775A1 (en) 2000-02-29 2001-09-07 Abbot F. Clark Diagnostics and therapeutics for glaucoma
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
AU2001280680A1 (en) * 2000-07-19 2002-01-30 Genzyme Corporation Phosphatonin-related gene and methods of use thereof
WO2002055547A2 (en) 2001-01-10 2002-07-18 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Sfrp and peptide motifs that interact with sfrp and methods of their use
EP1222933A1 (en) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
GB0111004D0 (en) * 2001-05-04 2001-06-27 Univ Sheffield Screening method
EP1452594A4 (en) * 2001-11-15 2007-01-10 Kyowa Hakko Kogyo Kk INDUCTOR FOR DIFFERENTIATING EMBRYOONAL STEM CELLS TO EODODERMAL CELLS, METHOD FOR OBTAINING THEM AND USE THEREOF
ATE500837T1 (de) * 2002-12-05 2011-03-15 Univ Arkansas Molekulare determinanten des multiplen myeloms und deren verwendung
WO2004090161A1 (en) * 2003-04-14 2004-10-21 Novartis Ag Gene expression associated with osteoblast differentiation
CN104726460A (zh) * 2013-12-22 2015-06-24 上海交通大学医学院 蛋白sFRP-5在治疗银屑病的药物中的应用
KR101835939B1 (ko) * 2014-08-26 2018-03-23 연세대학교 산학협력단 Wls 단백질의 특정 모티프를 인지하는 항체 및 이를 포함하는 약제학적 조성물
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
CN110361541A (zh) * 2019-07-23 2019-10-22 上海交通大学医学院附属瑞金医院 sFRP2和PCPE1作为联合靶点在制备纤维化疾病药物中的应用
CN114910454B (zh) * 2022-04-14 2025-06-13 中国人民解放军总医院第一医学中心 一种检测微重力条件下雄激素受体功能的方法
CN120714006A (zh) * 2025-07-11 2025-09-30 昆明理工大学 分泌型卷曲相关蛋白在制备关节炎治疗药物上的应用及关节炎治疗药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681701A (en) * 1993-07-12 1997-10-28 Mayo Foundation For Medical Education And Research Immortalized human fetal osteoblastic cells
ATE199721T1 (de) * 1994-07-04 2001-03-15 Takeda Chemical Industries Ltd Phosphonsäure verbindungen imre herstellung und verwendung
AU4981797A (en) * 1996-10-11 1998-05-11 Government Of The United States Of America, The Isolation and method of using tissue growth-inducing frzb protein
WO1998054325A1 (en) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Human frp and fragments thereof including methods for using them

Also Published As

Publication number Publication date
NZ529560A (en) 2005-05-27
JP2003512304A (ja) 2003-04-02
EP1212355A2 (en) 2002-06-12
WO2001019855A3 (en) 2002-01-24
IL148421A0 (en) 2002-09-12
CN1387537A (zh) 2002-12-25
CZ2002903A3 (cs) 2002-07-17
MXPA02002624A (es) 2002-07-30
CA2383360A1 (en) 2001-03-22
WO2001019855A2 (en) 2001-03-22
CN102988957A (zh) 2013-03-27
AU7131200A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
Wozney et al. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair
Canalis Effect of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariae
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
WO2001019855A3 (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
DE69841850D1 (de) Differenzierung in osteoblasten der fettgewebe-stromalen zellen und ihre verwendungen
Lee et al. Synergistic effect of growth factors on cell outgrowth from explants of rabbit anterior cruciate and medial collateral ligaments
BRPI0411552A (pt) anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
ES2088006T3 (es) Composiciones farmaceuticas osteoinductivas.
BR0214021A (pt) Células estromais derivadas de tecido adiposo, composições e métodos para o uso de tais células no tratamento e reparo de qualquer defeito associado ao tecido ocular
DE69630389D1 (de) Bioaktives verbundmaterial zum reparieren von hartem und weichem gewebe
ES2146552B1 (es) Peptidos inhibidores de tgf/31
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
DK0409472T3 (da) Knoglemorfogenetisk protein
AR014261A1 (es) Compuestos hipolipidemicos de benzotiazepina, composiciones y proceso para su preparacion
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ATE363533T1 (de) Osteoprotegerin bindende proteine und rezeptoren
Mouraret et al. Cell viability after osteotomy and bone harvesting: comparison of piezoelectric surgery and conventional bur
BRPI0411020A (pt) perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição
Calejo et al. Cellular complexity at the interface: challenges in enthesis tissue engineering
ATE404668T1 (de) Wachstumsfaktor-homologe zvegf-3
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
Schütze et al. Expression, purification, and functional testing of recombinant CYR61/CCN1

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.